Clinical Trial

Neutralizing Power of Serum Antibodies - 2

Study acronym: PNAS-2
Recruiting
View on ClinicalTrials.gov →
Summary
Severe forms of COVID-19 and Monkeypox affect immunocompromised and comorbid individuals. Vaccination and monoclonal antibody therapies induce neutralizing antibodies. This neutralizing power is recognized as a correlate of protection against a new infection. This study aims to describe the neutralizing power of serum and nasal antibodies over time, in relation to SARS-CoV-2 and MPXV vaccines or treatments received.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-24; most recent amendment 2025-12-12.
Status change: Not Yet Recruiting → Recruiting 2025-09-03
Trial Details
NCT Number NCT07085611
Lead Sponsor Centre Hospitalier Régional d'Orléans
Conditions COVID-19, SARS-CoV-2 Viraemia, Monkey Pox, Vaccination, Serum, Mucosal Immunity
Enrollment 30 participants
Start Date 2025-08-22
Primary Completion 2030-08-22 (estimated)
Study Completion 2035-07-11 (estimated)
Updated on ClinicalTrials.gov 2025-12-19